Objectives: heart failure is primarily a disease of elderly people. Current guidelines suggest all patients with suspected heart failure should undergo objective assessment, usually by echocardiography. In the UK resources are limited and not all patients have access to echocardiography. The electrocardiogram is widely used as a pre-screening investigation. Recently the natriuretic peptides have been shown to correlate well with left ventricular function, and evidence is accumulating which suggests that B-type natriuretic peptide may have a role in detecting cardiovascular disease. Elderly patients attending day hospital often have non-specific cardiovascular symptoms. B-type natriuretic peptide measurement in parallel with conventional electrocardiogram, may offer a novel method of identifying those with significant cardiac disease, which may warrant treatment. This study assessed the role of B-type natriuretic peptide and electrocardiogram in the detection of cardiac disease in patients attending Day Hospital. Design: prospective cohort study of patients referred to Day Hospital with suspected cardiovascular disease. Methods: this study prospectively evaluated 299 consecutive patients attending day hospital over a period of 13 months. Patients underwent clinical assessment, electrocardiography, echocardiography and natriuretic peptide measurement. Objective evidence of cardiac disease was based on electrocardiogram and echocardiographic findings. Setting: Medicine for the Elderly Day Hospital, Royal Victoria Hospital, Dundee. Main outcome measures: sensitivity, specificity, positive and negative predictive values of screening tests for left ventricular systolic dysfunction. Receiver-Operating-Characteristic curves for ability of B-type natriuretic peptide to detect cardiac disease (including left ventricular systolic dysfunction, valvular disease, atrial fibrillation and left ventricular hypertrophy). Mean B-type natriuretic peptide levels with 'incremental' levels of cardiovascular disease. Results: 299 patients (mean age 79; 65% female) completed the assessment. Ten percent of patients had left ventricular systolic dysfunction but 50% had objective evidence of cardiac disease. B-type natriuretic peptide was significantly elevated in patients with left ventricular systolic dysfunction, atrial fibrillation, left ventricular hypertrophy and valvular disease. Both B-type natriuretic peptide and the electrocardiogram were sensitive in detecting left ventricular systolic dysfunction but lacked specificity. Combining B-type natriuretic peptide with the electrocardiogram improved detection of left ventricular systolic dysfunction. B-type natriuretic peptide levels increased progressively as the number of different cardiac abnormalities increased. Conclusions: B-type natriuretic peptide may be a useful marker for cardiac disease in patients attending Day Hospital. Half of the patients assessed had cardiac disease detected. Both the electrocardiogram and B-type natriuretic peptide were sensitive in the detection of left ventricular systolic dysfunction but lacked specificity. B-type natriuretic peptide was superior to the electrocardiogram in the detection of valvular disease. If used to pre-screen cardiovascular disease in Day Hospital patients, B-type natriuretic peptide and the electrocardiogram could reduce the need for echocardiography in some patients before implementing evidence-based treatments. B-type natriuretic peptide increases progressively as the number of different cardiac abnormalities increases and this may explain why B-type natriuretic peptide is of such prognostic value in older patients.
Introduction
Heart failure is an important and increasing problem [1] [2] [3] . Proven treatments have been well described for heart failure due to left ventricular systolic dysfunction (LVSD) in both symptomatic and asymptomatic patients [4] [5] [6] [7] [8] [9] . Most new cases of heart failure present in elderly people [10] and the rising incidence and prevalence with advancing age is acknowledged [11] .
Accurate clinical diagnosis of heart failure is notoriously difficult [12] [13] [14] . Many people attending Day Hospital are likely to have structural cardiac disease, the diagnosis of which is hindered by multiple pathology and atypical presentation of disease. Echocardiography remains the standard investigation for the diagnosis of left ventricular systolic dysfunction although availability is resource-limited [15] . Identifying patients with significant cardiovascular disease is often possible from a history of previous myocardial infarction or an abnormal electrocardiogram. Recent evidence also suggests that the natriuretic peptides may be useful in detecting cardiac disease including left ventricular systolic dysfunction [16] [17] [18] [19] [20] . Levels of natriuretic peptides rise in response to ventricular wall stress and have been shown to be elevated in patients with left ventricular systolic dysfunction. Elevated levels of natriuretic peptides have also been found to be elevated in apparently healthy elderly people [21] as well as in patients with hypertension [22] . There are a number of natriuretic peptides and it appears that B-type natriuretic peptide (BNP) is more accurate than other natriuretic peptides in the detection of LVSD [23] . It is stable in whole blood and simple affordable radioimmunoassays are available for testing [24] making it possible for use in the Day Hospital setting.
As a result, we tested the possibility that BNP might be a good composite test reflecting a whole range of cardiac diseases (including valvular heart disease, atrial fibrillation and left ventricular hypertrophy rather than just LVSD) at the Day Hospital, as it provides strong prognostic information [25] .
Methods
The study prospectively evaluated all patients attending Day Hospital at the Royal Victoria Hospital in Dundee, over a period of 13 months from October 1998 to November 1999. A total of 440 patients were referred. Of these 55 failed to attend, 26 attended for repeated visits and 31 attended for one visit only or were admitted to hospital on their first attendance. Of the remaining 328, significant cognitive impairment was present in 24 who were unable to give informed consent, and thus excluded from study. All patients provided written informed consent and the study was approved by the Tayside Committee on Medical Research Ethics.
Clinical assessment was performed by a single experienced staff grade clinician. Symptoms, past medical history, medication and clinical signs including pulse, blood pressure, jugular venous pressure, basal crepitations, ankle oedema and murmurs were recorded. Each patient was categorised as either having definite evidence of heart failure or not. All patients had routine haematology and biochemistry including thyroid function and a standard 12-lead electrocardiogram (ECG). ECGs were analysed by two observers and coded according to Minnesota criteria [26, 27] . ECGs were coded abnormal if they showed: pathological Q-waves; bundle branch block pattern; interventricular conduction defect; ST/T segment abnormality; voltage criteria for LVH; atrial fibrillation/flutter. A detailed echocardiographic examination was performed in the Day Hospital by a single experienced sonographer using either a Toshiba Corevision system (SSA, UK) or Sim 7000 Challenge system (Esaote, Europe). Standard apical and parasternal views were obtained with patients supine in the left lateral position. M-mode recordings were made at the tips of the mitral leaflets from which end-diastolic and end-systolic diameters were derived to calculate fractional shortening if possible. Where M-mode measurements were suboptimal a regional wall motion score was calculated. Along with this a quantitative assessment was performed and overall left ventricular systolic function was graded as normal, mild, moderate or severely impaired. Full two dimensional and spectral Doppler studies were performed on each patient to define any coincidental valve disease. All images were stored on videotape. In cases where views were suboptimal or there was diagnostic doubt patients were referred for a second assessment performed by another experienced echocardiographer or for radionuclide ventriculography.
Following echocardiography patients were rested supine for a further 10 minutes. A 10 ml sample of venous blood was drawn into a tube containing edetic acid and aprotonin to prevent natriuretic hormone breakdown. Each sample was centrifuged for 15 minutes and plasma stored at -208C initially then transferred to a -708C freezer for long-term storage. Samples were measured in a single batch by an experienced technician who was unaware of clinical and echocardiographic findings. BNP was measured by a standard commercially available radioimmunoassay kit (Peninsula, UK) which has been used locally for several years [17, 20] .
Results
Patient characteristics are shown in Table 1 . Enquiring about a history of myocardial infarction (MI) was unrewarding as most patients were unsure whether a MI had been diagnosed. Two hundred and ninetynine participants had an analysable echocardiogram, electrocardiogram and BNP measured. Thirty-one patients (10.4%) had objective evidence of LVSD on echocardiography.
Ninety-two patients, (31%) had undergone echocardiography in the 4 years prior to assessment. Of the 48 patients with a previous diagnosis of Congestive Heart Failure (CHF) due to LVSD, 29 (60%) had undergone echocardiography. Of the 31 patients with confirmed LVSD 17 (55%) had previously undergone echocardiography.
One hundred and sixty-five (55%) of patients had an abnormal ECG. Twelve percent were in atrial fibrillation/flutter; 18% had voltage criteria for LVH; 16% had either pathological Q-waves or bundle branch block; 14% had poor r wave progression or interventricular conduction defect; 16% had ST/T segment changes or ischaemic changes.
The mean concentration of BNP was significantly higher in patients with LVSD than in those with normal left-ventricular function (P-0.001). Boxplots comparing BNP measurement in patients with LVSD and normal LV systolic function and receiver-operator-characteristic curves for BNP are shown in Figure 1 .
One hundred and fifty-five patients (52%) had objective evidence of cardiac disease defined as: LVSD or valvular disease on echocardiography; atrial flutter or fibrillation; evidence of previous myocardial infarction (pathological Q-waves or bundle branch block) on electrocardiography; evidence of left ventricular hypertrophy on echocardiography or by ECG voltage criteria. BNP was significantly elevated in this group of patients compared to those with no objective evidence of cardiac disease (P-0.001). Boxplots and receiver operator curves are shown in Figure 2 .
Patients with atrial fibrillation, valvular disease and left ventricular hypertrophy had significantly elevated BNP compared to those with no cardiovascular disease. The median BNPs with inter-quartile ranges in specific groups of patients with cardiac diseases are shown in Table 2 . Patients with cardiovascular disease showed a progressive rise in median BNP and IRQs with increasing number of cardiac diseases irrespective of the combination of diseases. Figure 3 shows boxplots of BNP in patients with no objective evidence of cardiac disease; one, two, three and four cardiac diseases. A normal electrocardiogram virtually excluded LVSD (sensitivity 97%) with 50% specificity. Definite evidence of previous MI on ECG was specific (88%) but not sensitive (48%). Table 3 gives the sensitivity, specificity and positive and negative predictive values for the detection of LVSD using ECG, BNP )35 and 49 pmol/l, history of ischaemic heart disease and combination of BNP and ECG.
Combining ECG and BNP improved specificity. Using a normal ECG as an initial pre screening tool, 134 of the 299 patients could be excluded and in those with an abnormal ECG and BNP -35 a further 37 were excluded with 2 missed cases of LVSD. Using BNP as the initial screening tool, 104 patients were excluded with one missed case of LVSD. In those with a BNP )35 pmol/l, a normal ECG excluded a further 
Discussion
This study provides new information about the diagnostic role of BNP in a cohort of older people attending day hospital. Compared with younger patients with no evidence of cardiovascular disease, the mean BNP was higher in this population, which is compatible with suggestions that BNP rises in response to normal ageing. However, those older patients with cardiovascular disease in this cohort had significantly elevated BNP levels compared to those with 'healthy hearts'. Importantly, BNP levels rose progressively in patients with one, two, three and four cardiac diseases which may explain why BNP is such a good prognostic indicator in elderly patients in the community with no apparent cardiac disease [25] . These observations suggest that BNP may be a useful indicator of clinically significant cardiovascular disease in an older patient and may be useful in distinguishing 'normal' ageing from pathological cardiac abnormalities which could be treated.
Although raised BNP was extremely sensitive in detecting LVSD and cardiovascular disease it lacked specificity. Only one in 7 patients with a raised BNP over 35 would have LVSD. As in previous studies a normal ECG was extremely effective in ruling out LVSD and had similar sensitivity/specificity as BNP. Patients were often unable to tell if a previous episode of chest pain had been angina, a MI or non-cardiac chest pain. Review of casenotes and information from GP's was often unhelpful or inaccurate. Furthermore using definite evidence of MI on ECG was specific but lacked sensitivity, making it ineffective as a prescreening tool as many cases of LVSD would be missed. Clearly LVSD is not the only cause of breathlessness in the older patient. It may be that atrial fibrillation or valvular disease; diastolic dysfunction or chest disease could explain symptoms suggestive of heart failure. However the absolute levels of BNP are greater in patients with LVSD which is consistent with the relatively poor prognosis in these patients compared to those with normal systolic function heart failure. Currently the treatment options for LVSD are clear and this group should be a priority for identification because of its treatment implications. A moderately elevated BNP may suggest that a patient's symptoms could be a result of atrial fibrillation, valvular disease or left ventricular hypertrophy. These patients often have hypertension which should be treated and patients with atrial fibrillation should be considered for anticoagulation.
In this group of patients 40% were taking frusemide with only 16% of them having a prior diagnosis of heart failure. This highlights how common it is to suspect 'heart failure' in this population. There was little correlation between a patient being on frusemide and them having LVSD. This may be partially explained by normal systolic function heart failure. The current data suggests that half of the patients attending Day Hospital had some objective evidence of cardiovascular disease i.e. LVSD, valvular disease, atrial fibrillation or left ventricular hypertrophy.
Combining ECG and BNP improved detection of LVSD. Patients with an abnormal ECG and BNP )49 had a 1 in 4 chance of having LVSD with a 98% negative predictive value. This would obviate the need for echocardiography in about one-third of cases.
BNP was superior to ECG in the detection of valvular disease and again about one third of patients could be excluded from screening by echocardiography, but 8 cases of moderate to severe valvular disease would However there are some potential theoretical advantages to BNP over the ECG in selecting patients for echocardiography, especially in general practice. Firstly, general practitioners are not as confident at analysing ECGs as hospital consultants. In one study where the ECGs were analysed by general practitioners, GP's missed 27% of cases of LVSD when they used an ECG to pre-screen [26] . In another study GP's missed 10% of LVSD cases [27] . Secondly, in our local area one third of GP practices have no ECG machine. Thirdly, the ECG is a categorical variable which has to be graded as normal or abnormal for this purpose. BNP has the advantage of being a continuous variable, which means one can choose any appropriate cut-off to suit the clinical purpose, i.e. BNP has more flexibility as a test than an ECG. The graded nature of BNP means that it not only identifies cardiac abnormalities but it also identifies the severity of the abnormality detected. Another advantage of BNP measurement is that it can be standardized better since it is measured more consistently by an approved laboratory with regular quality control rather than a multitude of different doctors interpreting the ECG, and it is now available for bedside testing like a glucometer, which gives instant results and makes it as simple if not quicker than an ECG.
In conclusion, BNP and ECG, performed equally well at excluding LVSD and other cardiac diseases in a cohort of older patients. However, BNP was superior to the ECG in excluding significant cardiac valvular disease. BNP levels increased progressively as the number of different cardiac abnormalities increased, which may explain why BNP is a good predictor of prognosis in patients with cardiovascular disease. More widespread use of BNP measurements in clinical practice may facilitate the optimum detection and treatment of cardiovascular disease while making the most efficient use of resources.
Key points
. Cardiac disease is common in the older patient. . Symptoms are often non-specific and objective assessments of cardiac performance are essential before commencing treatment.
. B-Type natriuretic peptide can identify cardiac disease in a Day Hospital Population. . BNP levels rise incrementally with the number of cardiac diagnoses. . BNP measurement, in conjunction with ECG, may reduce the need for echocardiography in some patients before commencement of evidence-based treatments.
